Trubion Starts Lupus Trial

3/25/09Follow @xconomy

Trubion Pharmaceuticals (NASDAQ: TRBN), said today it has started a clinical trial of a drug for lupus, an autoimmune disease. The drug, SBI-087, is made to hit a target called CD20, that’s currently blocked by Genentech and Biogen Idec’s rituximab (Rituxan) for patients with a different form of autoimmune disease, rheumatoid arthritis. The Trubion drug-which is also being tested for rheumatoid arthritis—is being developed in partnership with Madison, NJ-based Wyeth.

By posting a comment, you agree to our terms and conditions.